Leica Biosystems and Bio-Techne Announce the US Launch of RNAscope In Situ Hybridization Automation on the BOND-PRIME Staining Platform

Melbourne, Australia — (March 17, 2026) — Leica Biosystems, a Danaher company and a global leader in anatomic pathology solutions, and Bio-Techne (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, announce the US launch of BOND-PRIME RNAscope Brown Detection, enabling automation of RNAscope™ in situ hybridization (ISH) on the BOND-PRIME IHC/ISH staining platform. This combination brings together Bio-Techne’s industry-leading RNAscope technology with the speed of the BOND-PRIME platform from Leica Biosystems, empowering pathologists with access to deeper molecular understanding and enhancing laboratory efficiency.

As anatomic pathology laboratories face pressure to deliver timely results, the RNAscope workflow on the BOND-PRIME provides RNA detection with full spatial and morphological context, automated on a flexible platform built for high-throughput laboratories. RNAscope can run in less than 8 hours, enabling laboratories to achieve rapid turnaround times without compromising staining quality. This integration brings together Bio-Techne’s proven RNA ISH capabilities with Leica Biosystems’ commitment to workflow innovation, helping laboratories streamline operations while maintaining the highest standards in staining consistency.

The collaboration between Leica Biosystems and Bio-Techne expands access to advanced RNA ISH technology for clinical laboratories across the United States. By making this powerful technology available on the fully automated BOND-PRIME platform in addition to the BOND-III staining system, more laboratories can bring high-quality molecular insights directly into their assay workflows, helping pathologists deliver faster results.

“Leica Biosystems continues to lead by advancing pathology through innovation that accelerates results and delivers deeper diagnostic insights,” said Karan Arora, Senior Vice President of Advanced Assays, AI, and Pharma Partnerships at Leica Biosystems. “By bringing RNAscope® assays to the BOND-PRIME platform, we enable laboratories to deliver high-quality RNA in situ hybridization results faster and more efficiently.”

“At Bio-Techne, we are committed to advancing molecular diagnostics that empower pathologists,” said Steve Crouse, President of Bio-Techne’s Diagnostics and Spatial Biology Segment. “We’re excited to enable RNAscope’s gold-standard RNA in situ hybridization technology on the fully automated BOND-PRIME platform, empowering laboratories to achieve high-quality staining in high-volume clinical settings.”

RNAscope™ is a spatial RNA detection technology that visualizes single RNA molecules within intact cells and tissues using a proprietary double-Z probe design, delivering an exceptional signal-to-noise ratio even in FFPE specimens. RNAscope has become a trusted solution for anatomic pathologists and researchers seeking spatial context for molecular biomarkers.

Building on its legacy of excellence in advanced staining technology and pathology processes, the BOND-PRIME platform makes it easier for laboratories to quickly and consistently deliver complete cases to pathologists. With optimal patient care depending on an accurate and timely diagnosis, the latest advancement to the BOND-PRIME stainer incorporates a unique set of productivity innovations to support pathology laboratories’ drive for procedural efficiency and staining quality.

For more information, Click here.

BOND-PRIME RNAscope Brown Detection is a General-Purpose Reagent (GPR).

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.

Leica Biosystems:  Matt McCutcheon, Global External Communications Senior Manager, Leica Biosystems matthew.mccutcheon@leicabiosystems.com

Bio-Techne: Corporate Communications media.relations@bio-techne.com
David Clair, Vice President, Investor Relations david.clair@bio-techne.com

Source: Leica Biosystems